HASHEM EL-SERAG to Medicare
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Medicare.
Connection Strength
1.290
-
Bundling in medicare patients undergoing bidirectional endoscopy: how often does it happen? Clin Gastroenterol Hepatol. 2014 Jan; 12(1):58-63.
Score: 0.334
-
Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006 Jan; 44(1):158-66.
Score: 0.195
-
Concurrence of inflammatory bowel disease with multiple sclerosis or Hodgkin lymphoma. Eur J Gastroenterol Hepatol. 2023 12 01; 35(12):1349-1353.
Score: 0.169
-
Limited life expectancy among a subgroup of medicare beneficiaries receiving screening colonoscopies. Clin Gastroenterol Hepatol. 2014 Mar; 12(3):443-450.e1.
Score: 0.084
-
Patient-centered, comparative effectiveness of esophageal cancer screening: protocol for a comparative effectiveness research study to inform guidelines for evidence-based approach to screening and surveillance endoscopy. BMC Health Serv Res. 2012 Aug 28; 12:288.
Score: 0.078
-
Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J Clin Gastroenterol. 2012 Jan; 46(1):71-7.
Score: 0.075
-
Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. Hepatology. 2011 Jan; 53(1):42-52.
Score: 0.070
-
Hepatocellular cancer care: cost is important but only one factor of disease burden. J Hepatol. 2009 Jan; 50(1):10-2.
Score: 0.060
-
Temporal trends in new and recurrent oesophageal strictures in a Medicare population. Aliment Pharmacol Ther. 2007 May 15; 25(10):1223-9.
Score: 0.054
-
The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs. Arch Intern Med. 2006 Nov 13; 166(20):2202-8.
Score: 0.052
-
Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004 Nov; 127(5):1372-80.
Score: 0.046
-
Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes Control. 2021 Apr; 32(4):317-325.
Score: 0.035
-
Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013 Aug; 108(8):1314-21.
Score: 0.021
-
Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011 Aug; 54(2):463-71.
Score: 0.018